BRANDY HAWKINS: Open Payments
NPI 1164049359 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$583 in 27 payments from 13 companies in 2025. Trend: 2023 $1,337 · 2024 $1,643 · 2025 $583
Food & beverage: $583
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $194 |
| Janssen Biotech, Inc. | 3 | $66 |
| Ardelyx, Inc. | 2 | $59 |
| Aimmune Therapeutics, Inc. | 1 | $46 |
| Madrigal Pharmaceuticals | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| GENZYME CORPORATION | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
Products named: SKYRIZI, TREMFYA, IBSRELA, ZENPEP, RINVOQ, REZDIFFRA, XIFAXAN, LINZESS.
Industry payments across LA — which companies pay providers there.
